The molecular mechanism on the association of diabetes mellitus with hepatocellular carcinoma
Keywords:Diabetes mellitus, Hepatocellular carcinoma, Insulin-like growth factor, Toll-like receptor 4, NCOA5
Many studies have shown a complex link between diabetes mellitus and hepatocellular carcinoma. Diabetes mellitus is an independent risk factor for the development of hepatocellular carcinoma (HCC), and increase both the morbidity and mortality of HCC in many ways, including insulin resistance, hyperglycemia, hyperinsulinemia, inflammation and metabolic dysfunction. Insulin-like growth factor (IGF) axis, WNT/β-catenin pathway and glycogen synthase kinase 3 (GSK3) were dysregulated in liver metabolism of diabetics and cause damage to hepatocytes, which would increase risk for HCC. The toll-like receptor 4 (TLR4) could affect the two diseases through the NF-κB pathway, when the liver is under metabolic dysfunction. Moreover, single nucleotide variation (SNV) (T445A) in NCOA5 is a confirmed pathogenic in these HCC patients with diabetes mellitus.
Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145-58.
Rendell M, Akturk HK, Tella SH. Glargine safety, diabetes and cancer. Expert Opin Drug Saf. 2013;12(2):247-63.
Umetsu S, Mizukami H, Saito T, Uchida C, Igawa A, et al. Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylation. Scientific Rep. 2020;10(1):1156.
Mori M, Saitoh S, Takagi S. A Review of Cohort Studies on the Association Between History of Diabetes Mellitus and Occurrence of Cancer. Asian Pac J Cancer Prev. 2000;1(4):269-76.
Wang C, Wang X, Gong G. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130(7):1639-48.
Niwa Y, Ishikawa K, Ishigami M. Effect of hyperglycemia on hepatocellular carcinoma development in diabetes. Biochem Biophys Res Commun. 2015;463(3):344-50.
He G, Yu GY, Temkin V. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell. 2010;17(3):286-97.
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nature Rev Immunol. 2011;11(2):98-107.
Mendonca FM, de Sousa FR, Barbosa AL. Metabolic syndrome and risk of cancer: which link? Metabolism. 2015;64(2):182-9.
Bell DS, Allbright E. The multifaceted associations of hepatobiliary disease and diabetes. Endocr Pract. 2007;13(3):300-12.
Lombay B, Szilagyi R, Szalay F. Type 2 diabetes mellitus, insulin resistance and hepatocellular carcinoma in chronic hepatitis C patients. Data from Northeastern Hungary. Orv Hetil. 2019;160(40):1591-602.
Denduluri SK, Idowu O, Wang Z. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis. 2015;2(1):13-25.
Singh MK, Das BK, Choudhary S. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. Biomed Pharmacother, 2018;106:991-1002.
Martinez-Quetglas I, Pinyol R, Dauch D. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Gastroenterology. 2016;151(6):1192-205.
Ampuero J, Romero-Gomez M. Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. World J Hepatol. 2015;7(8):1105-11.
Elghazi L, Gould AP, Weiss AJ. Importance of beta-Catenin in glucose and energy homeostasis. Scientific Rep. 2012;2:693.
Ferrarini A, Di Poto C, He S. Metabolomic Analysis of Liver Tissues for Characterization of Hepatocellular Carcinoma. J Proteome Res. 2019;18(8):3067-76.
Liu P, Chen B, Gu Y. PNMA1, regulated by miR-33a-5p, promotes proliferation and EMT in hepatocellular carcinoma by activating the Wnt/beta-catenin pathway. Biomed Pharmacother. 2018;108:492-9.
Senni N, Savall M, Cabrerizo Granados D. Beta-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut. 2019;68(2):322-34.
Hung MH, Chen YL, Chen LJ. Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced beta-catenin activation. Cell Death Dis. 2019;10(6):420.
Cervello M, Augello G, Cusimano A. Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma. Adv Biol Regul. 2017;65:59-76.
Gattinoni L, Ji Y, Restifo NP. Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. Clin Cancer Res. 2010;16(19):4695-701.
Jin H, Yang X, Zhao K. Glycogen synthase kinase-3 beta inhibitors protectagainst the acute lung injuries resulting from acute necrotizing pancreatitis. Acta Cir Bras. 2019;34(6):201900609.
Qiao G, Le Y, Li J. Glycogen synthase kinase-3beta is associated with the prognosis of hepatocellular carcinoma and may mediate the influence of type 2 diabetes mellitus on hepatocellular carcinoma. PloS one. 2014;9(8):105624.
Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, et al. Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. Hepatology. 2019.
Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263-73.
White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10(12):1342-59.
Hu M, Phan F, Bourron O. Steatosis and NASH in type 2 diabetes. Biochimie. 2017;143:37-41.
Takeda Y, Fujita Y, Bessho R. Increment of plasma glucose by exogenous glucagon is associated with present and future renal function in type 2 diabetes:a retrospective study from glucagon stimulation test. BMC Endocr Disord. 2019;19(1):99.
Lee JY, Sohn KH, Rhee SH. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. 2001;276(20):16683-9.
Shen C, Ma W, Ding L. The TLR4-IRE1alpha pathway activation contributes to palmitate-elicited lipotoxicity in hepatocyte. J Cell Mol Med. 2018;22(7):3572-81.
Kanda T, Goto T, Hirotsu Y. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Int J Mol Sci. 2020;21(4).
Nadal A, Alonso-Magdalena P, Soriano S. The role of oestrogens in the adaptation of islets to insulin resistance. J Physiol. 2009;587(21):5031-7.
Dhar D, Seki E, Karin M. NCOA5, IL-6, type 2 diabetes, and HCC: The deadly quartet. Cell Metab. 2014;19(1):6-7.
Chan LC, Li CW, Xia W. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Investig. 2019;129(8):3324-38.
Gao S, Li A, Liu F. NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. Cancer Cell. 2013;24(6):725-37.
Liu X, Liu F, Gao S. A single non-synonymous NCOA5 variation in type 2 diabetic patients with hepatocellular carcinoma impairs the function of NCOA5 in cell cycle regulation. Cancer letters. 2017;391:152-61.